UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 10-Q/A

              [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                 For the Quarterly Period Ended October 31, 1997

                                       OR

              [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                For the Transition Period From ________to________

                         Commission file number 0-17019

                               ANGEION CORPORATION
             (Exact name of registrant as specified in its charter)

                Minnesota                           41-1579150
        (State of Incorporation)         (IRS Employer Identification No.)
                Suite 170
 7601 Northland Drive, Minneapolis, MN              55428-1088
          (Address of principal                     (Zip Code)
            executive offices)


                                 (612) 315-2000
                               (Telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

                                YES __X__ NO ____

            Common stock, par value $.01 per share: 32,955,041 shares
                       outstanding as of December 10, 1997

<PAGE>

                                EXPLANATORY NOTE

         Angeion Corporation (the "Company") filed a request for Confidential
Treatment on December 14, 1997 (the "Request") in connection with certain
transactions with Synthelabo and its subsidiaries. The documents related to such
transactions were originally included as exhibits to the Company's original Form
10-Q filed on December 15, 1997. Pursuant to discussions with the Securities and
Exchange Commission regarding the Request, the Company is refiling such
documents in their final redacted forms as exhibits to this Form 10-Q/A.

<PAGE>

                    ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.

(a)  Exhibits

                                                                     Method of
Item No.          Item                                                Filing
--------          ----                                                ------

10.1              Amended and Restated Investment and Master          Filed
                  Strategic Relationship Agreement dated as of        herewith.
                  October 9, 1997 between Company and
                  Synthelabo.*

10.2              Limited Liability Company Operating                 Filed    
                  Agreement of Angellan Medical Systems, LLC          herewith.
                  dated December 9, 1997 between the Company     
                  and ELA Medical, Inc.*

10.3              Implantable Cardioverter Defibrillator              Filed    
                  Product Manufacturing and Supply Agreement          herewith.
                  dated December 9, 1997 between the Company          
                  and ELA Medical, Inc.*

10.4              Implantable Cardioverter Defibrillator              Filed    
                  Product Manufacturing and Supply Agreement          herewith.
                  dated December 9, 1997 between the Company          
                  and Angellan Medical Systems, LLC.*

10.5              First Amendment to Rights Agreement dated as        Filed    
                  of October 9, 1997 between the Company and          herewith.
                  Norwest Bank Minnesota, N.A.                        

10.6              Second Amendment to Rights Agreement dated          Filed    
                  as of October 9, 1997 between the Company           herewith.
                  and Norwest Bank Minnesota, N.A.                   

10.7              Form of Common Stock Purchase Warrant to            Filed    
                  purchase 1,350,845 shares of Common Stock           herewith.
                  issued to Synthelabo.                               

10.8              Form of Supplemental Common Stock Purchase          Filed    
                  Warrant.                                            herewith.

10.9              Form of Second Investment Common Stock              Filed    
                  Purchase Warrant.                                   herewith.

10.10             Form of Third Investment Common Stock               Filed    
                  Purchase Warrant.                                   herewith.

10.11             Form of Fourth Investment Common Stock              Filed    
                  Purchase Warrant.                                   herewith.

10.12             1994 Non-Employee Director Plan (as amended         **
                  through September 30, 1997).

10.13             1997 Employee Stock Purchase Plan.                  **

10.14             Side Letter between Company and Synthelabo          Filed    
                  dated as of December 9, 1997.                       herewith.

27.1              Financial Data Schedule.                            **

(b)  A current report on Form 8-K, dated October 22, 1997, was filed during the
     three months ended October 31, 1997, pursuant to Item 5. This filing was
     made in reference to the announcement by the Company of change in its
     fiscal year-end from July 31 to December 31. No financial statements were
     included in this filing.

*    Confidential treatment has been requested with respect to designated
     portions contained within this exhibit. Such portions have been omitted and
     filed separately with the Commission pursuant to Rule 24b-2 of the
     Securities and Exchange Act of 1934, as amended.

**   Incorporated by reference to the original Form 10-Q filed by the Company on
     December 15, 1997.

<PAGE>


                                   SIGNATURES


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                            ANGEION CORPORATION

                                       By: /s/ James B. Hickey, Jr.
                                           -------------------------------------
                                           James B. Hickey, Jr.
                                           President and Chief Executive Officer

July 29, 1998